Latest News
Scientist at Work - Rob Holman - So Much to Learn About the Oceans From Sand - Biography - NYTimes.com
New York Times, The | 13 minutes ago
CORVALLIS, Ore. As a young geophysicist in the 1980s, Rob Holman attended a conference in San Francisco that included a field trip to a beach. Dr. Holman, who grew up inland, in Ottawa, stared at the ocean, assessing the strengths and vectors of the waves and currents. But when he looked around, everyone else was studying the sand. He realized, he recalled, that sand is not the same everywhere. So he started collecting it. I collected a few samples and put them in jars, he said. Then...... (more)
CRIME REPORT: Cars pounded by rocks hurled from bridge over Paul Barret Parkway : Local News : Memphis Commercial Appeal
Commercial Appeal (Memphis, Tenn.), The | 2 hours 13 minutes ago
Three vehicles, including a patrol car, have been pounded by rock or concrete chunks hurled from the Donnell Road bridge over Paul Barret Parkway in North Shelby County.... (more)
Endo to buy Indevus for $370 million upfront
Boston Globe, The | 2 hours 17 minutes ago
NEW YORK—Endo Pharmaceutical Holdings Inc. said Monday it will buy Indevus Pharmaceuticals Inc. for $370 million upfront, or $4.50 per share, acquiring Invedus' urology and hormone drug candidates in the process.... (more)
Quidel CEO Caren L. Mason to retire June 1
Boston Globe, The | 2 hours 17 minutes ago
SAN DIEGO—Diagnostics maker Quidel Corp. said Monday its president and chief executive, Caren L. Mason, plans to retire on June 1.... (more)
Investor's Business Daily: Biotech Firm Sticks To Its Work While Drug Giant Roche Circles
Investor's Business Daily | 3 hours 5 minutes ago
Posted 1/5/2009 Last summer, Genentech (DNA) rejected Swiss drug maker Roche Holding's $43.7 billion offer to buy the company. The $89-a-share bid was too low, the biotech giant's board said, but it kept the door open for a higher bid.... (more)
Biogen shares fall on JP Morgan downgrade - Forbes.com
Forbes | 4 hours 52 minutes ago
Shares of Biogen Idec Inc. fell Monday after JP Morgan cut its rating on the stock, saying the multiple sclerosis drug Tysabri could continue facing challenges in 2009 while the company lacks any catalysts to drive new revenue.... (more)
Endo To Buy Indevus - Forbes.com
CNS Magazine | 4 hours 59 minutes ago
Endo Pharmaceuticals, best known for the pain drugs Percocet and Lidoderm, plans to purchase Indevus Pharmaceuticals, a maker of treatments for urinary incontinence for $370 million in cash now and, in a twist, $267 million more if it hits certain regulatory and sales milestones, the companies said.... (more)
Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals - Press Releases: PR Newswire: Utilities - SunHerald.com
Sun Herald (Biloxi-Gulfport, Miss.), The | 5 hours 35 minutes ago
"For many reasons, we are very pleased to bring this transaction to the shareholders and other stakeholders of the Company," said Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "For our shareholders, the deal not only captures a significant premium in the up-front portion of the consideration, but our investors will also maintain a significant interest in the downstream value creation from NEBIDO and the octreotide implant.... (more)
ConMed Struck Down By Dollar Gain - Forbes.com
Forbes | 7 hours 44 minutes ago
ConMed was already wounded last year by penny-pinching hospital administrators, but what really scarred the maker of minimally invasive surgical equipment was the unexpected revival of the dollar in the fourth quarter.... (more)
Sector Snap: Medical technology shares slide - Forbes.com
Forbes | 7 hours 44 minutes ago
Shares of medical technology companies mostly traded lower Monday after an Oppenheimer analyst predicted hospitals will cut their spending by 15 percent to 25 percent in 2009, and reduced his estimates on a half dozen companies.... (more)
Immunogen names new CEO
American City Business Journals | 10 hours 59 minutes ago
Immunogen Inc., the Waltham-based biotechnology company, announced the departure of CEO Mitchell Sayare and the installment of Daniel Junius as the new CEO. Sayare will continue to serve as Chairman of the Board and as a director of the company.... (more)
Analyst sees slowdown in large-diameter pipe demand - 12/30/2008 12:51:00 PM - Purchasing
Purchasing.com | 11 hours 36 minutes ago
IHS Global Insight analyst KC Chang in Washington doesn’t expect a rebound in new large-diameter pipe orders until oil and natural gas prices regain traction and credit markets improve. The decline in demand and lower costs of production in 2009 “will create significant downward pricing pressure,” he adds.... (more)
Chipmakers struggle to finance operations amid slumping demand - 12/30/2008 1:09:00 PM - Purchasing
Purchasing.com | 11 hours 36 minutes ago
The dramatic downturn in demand and price for semiconductors has a host of chipmakers scrambling to adjust capacity and secure loans and financing to ride out losses in what could be an extended slump that drives chip industry consolidation.... (more)
36 Stories | 
RSS Feed
Sign up for AABB SmartBrief
Companies in the news
- Alexion Pharmaceuticals
- Amgen Inc.
- Arrow International Inc.
- Ball Memorial Hospital
- Catholic Healthcare West
- Genentech Inc
- Gilead Sciences Inc
- Immunogen Inc.
- Infinity Pharmaceuticals Inc.
- Logistics
- Shelby County
- St. Jude Children Research Hospital
- Stryker Corp
- Sutter Health
- Teleflex Inc